by Elena Iemma | Oct 22, 2025 | Blog
The Power of Tregs: From Sakaguchi’s Nobel Discovery to EpiVax Innovation If you know us, you know we love Tregs. Regulatory T cells (Tregs) are central to how we think about the immune system and nearly everything we do at EpiVax. So, we were thrilled to see this...
by Elena Iemma | Aug 19, 2025 | Blog
The Tregs as Medicine Symposium September 26, 2025 | The Westin Hotel, Meguro Tokyo The Tregs as Medicine: Tolerance and InTolerance Symposium will bring together leading scientists and clinicians to examine how regulatory T cells (Tregs) and tolerance...
by Elena Iemma | Jul 29, 2025 | Blog
Optimize Your Immunogenicity Strategy with Trusted Expert Advice Immunogenicity is a critical factor in biologic drug development, with the potential to determine a therapy’s success or failure. Undesirable immune responses, including the formation of anti-drug...
by Elena Iemma | Jul 17, 2025 | Blog
Tregs, Epitopes, and the Future of Immune Tolerance Making Sense of Natural Constraint Contrary to popular (immunologist) belief, there’s nothing ‘non-specific’ about Tregs! Otherwise why would they carry TCR (T cell receptors) that bind to their...
by Elena Iemma | May 28, 2025 | Blog, Uncategorized
The new CSO starts on June 1st! Drumroll please…. We are pleased to welcome Dr. Vibha Jawa as the new Chief Scientific Officer at EpiVax! Please see this link for more information about this latest update to EpiVax 2.0. (I will be around to help transition)....
